Metomidate-based imaging of adrenal masses

Hormones and Cancer

Volumn 2, Issue 6, 2011, Pages 348-353

  Hahner, S ^a   Sundin, A ^b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

11C metomidate PET; Adrenal imaging; Adrenal tumors; Metomidate SPECT

Indexed keywords

6BETA IODOMETHYL 19 NORCHOLEST 5(10) EN 3BETA OL I 131; ALDOSTERONE SYNTHASE; ANTINEOPLASTIC AGENT; CARBON 11; FLUORODEOXYGLUCOSE F 18; IODINE 123; IODOMETOMIDATE; METOMIDATE; UNCLASSIFIED DRUG;

ADRENAL CANCER; ADRENAL CORTEX CARCINOMA; ADRENAL CORTEX CELL; ADRENAL METASTASIS; ADRENAL TUMOR; ARTICLE; BINDING AFFINITY; CANCER CHEMOTHERAPY; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DRUG BINDING; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG UPTAKE; HUMAN; NEEDLE BIOPSY; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SCINTIGRAPHY; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR DIFFERENTIATION;

ADRENAL GLAND NEOPLASMS; ADRENAL GLANDS; ADRENOCORTICAL CARCINOMA; ANIMALS; CARBON RADIOISOTOPES; DIAGNOSIS, DIFFERENTIAL; EARLY DETECTION OF CANCER; ETOMIDATE; HUMANS; NEOPLASM METASTASIS; PHEOCHROMOCYTOMA; POSITRON-EMISSION TOMOGRAPHY; RADIOACTIVE TRACERS; STEROID 11-BETA-HYDROXYLASE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 83555177206     PISSN: 18688497     EISSN: 18688500     Source Type: Journal    
DOI: 10.1007/s12672-011-0093-3     Document Type: Article

References (40)

1. Abrams HL, Spiro R, Goldstein N (1950) Metastases in carcinoma; analysis of 1000 autopsied cases. Cancer 3(1): 74-85.
2. Bergstrom M, Bonasera TA, Lu L, Bergstrom E, Backlin C, Juhlin C, Langstrom B (1998) In vitro and in vivo primate evaluation of carbon-11-etomidate and carbon-11-metomidate as potential tracers for PET imaging of the adrenal cortex and its tumors. J Nucl Med 39(6): 982-989.
3. Boland GW, Blake MA, Holalkere NS, Hahn PF (2009) PET/CT for the characterization of adrenal masses in patients with cancer: qualitative versus quantitative accuracy in 150 consecutive patients. AJR Am J Roentgenol 192(4): 956-962.
4. Boland GW, Dwamena BA, Jagtiani Sangwaiya M, Goehler AG, Blake MA, Hahn PF, Scott JA, Kalra MK (2011) Characterization of adrenal masses by using FDG PET: a systematic review and meta-analysis of diagnostic test performance. Radiology 259(1): 117-126.
5. Boland GW, Goldberg MA, Lee MJ, Mayo-Smith WW, Dixon J, McNicholas MM, Mueller PR (1995) Indeterminate adrenal mass in patients with cancer: evaluation at PET with 2-[F-18]-fluoro-2-deoxy-d-glucose. Radiology 194(1): 131-134.
6. Boland GW, Lee MJ, Gazelle GS, Halpern EF, McNicholas MM, Mueller PR (1998) Characterization of adrenal masses using unenhanced CT: an analysis of the CT literature. AJR Am J Roentgenol 171(1): 201-204.
7. Brady MJ, Thomas J, Wong TZ, Franklin KM, Ho LM, Paulson EK (2009) Adrenal nodules at FDG PET/CT in patients known to have or suspected of having lung cancer: a proposal for an efficient diagnostic algorithm. Radiology 250(2): 523-530.
8. Caoili EM, Korobkin M, Brown RK, Mackie G, Shulkin BL (2007) Differentiating adrenal adenomas from nonadenomas using (18)F-FDG PET/CT: quantitative and qualitative evaluation. Acad Radiol 14(4): 468-475.
9. Caoili EM, Korobkin M, Francis IR, Cohan RH, Dunnick NR (2000) Delayed enhanced CT of lipid-poor adrenal adenomas. AJR Am J Roentgenol 175(5): 1411-1415.
10. Caoili EM, Korobkin M, Francis IR, Cohan RH, Platt JF, Dunnick NR, Raghupathi KI (2002) Adrenal masses: characterization with combined unenhanced and delayed enhanced CT. Radiology 222(3): 629-633.
11. Chong S, Lee KS, Kim HY, Kim YK, Kim BT, Chung MJ, Yi CA, Kwon GY (2006) Integrated PET-CT for the characterization of adrenal gland lesions in cancer patients: diagnostic efficacy and interpretation pitfalls. Radiographics 26(6): 1811-1824, discussion 1824-1816.
12. Christensen J, Fosse RT, Halvorsen OJ, Morild I (1987) Comparison of various anesthetic regimens in the domestic fowl. Am J Vet Res 48(11): 1649-1657.
13. Copeland PM (1983) The incidentally discovered adrenal mass. Ann Intern Med 98(6): 940-945.
14. Gerard H, Sensky PL, Broom DM, Perremans S, Geers R (1996) Influences of type of anaesthesia on cortisol, beta-endorphin and heart rate in pigs. Vet Res 27(3): 219-226.
15. 131I-iodometomidate radiotherapy for metastatic adrenocortical carcinoma-first clinical experience. Endocrine Abstracts, Abstract Book of the 11th European Congress of Endocrinology, OR0483.
16. 123I]Iodometomidate for molecular imaging of adrenocortical cytochrome P450 family 11B enzymes. J Clin Endocrinol Metab 93(6): 2358-2365.
17. 18F-FDG positron emission tomography scanning. Int J Clin Pract 61(5): 802-809.
18. 11C-metomidate positron emission tomography for evaluation of adrenal incidentalomas. Eur J Radiol 69(2): 314-323.
19. 11C]metomidate positron emission tomography of adrenocortical tumors in correlation with histopathological findings. J Clin Endocrinol Metab 91(4): 1410-1414.
20. 11C-metomidate positron emission tomography after dexamethasone suppression for detection of small adrenocortical adenomas in primary aldosteronism. Langenbecks Arch Surg 395(7): 963-967. doi: 10. 1007/s00423-010-0681-7.
21. Jana S, Zhang T, Milstein DM, Isasi CR, Blaufox MD (2006) FDG-PET and CT characterization of adrenal lesions in cancer patients. Eur J Nucl Med Mol Imaging 33(1): 29-35.
22. Kebapci M, Kaya T, Gurbuz E, Adapinar B, Kebapci N, Demirustu C (2003) Differentiation of adrenal adenomas (lipid rich and lipid poor) from nonadenomas by use of washout characteristics on delayed enhanced CT. Abdom Imaging 28(5): 709-715.
23. 11C-metomidate PET imaging of adrenocortical cancer. Eur J Nucl Med Mol Imaging 30(3): 403-410.
24. Kim HK, Choi YS, Kim K, Kim J, Shim YM (2007) Preoperative evaluation of adrenal lesions based on imaging studies and laparoscopic adrenalectomy in patients with otherwise operable lung cancer. Lung Cancer 58(3): 342-347. doi: 10. 1016/j. lungcan. 2007. 07. 001.
25. Korobkin M, Brodeur FJ, Francis IR, Quint LE, Dunnick NR, Londy F (1998) CT time-attenuation washout curves of adrenal adenomas and nonadenomas. AJR Am J Roentgenol 170(3): 747-752.
26. Korobkin M, Giordano TJ, Brodeur FJ, Francis IR, Siegelman ES, Quint LE, Dunnick NR, Heiken JP, Wang HH (1996) Adrenal adenomas: relationship between histologic lipid and CT and MR findings. Radiology 200(3): 743-747.
27. Korobkin M, Lombardi TJ, Aisen AM, Francis IR, Quint LE, Dunnick NR, Londy F, Shapiro B, Gross MD, Thompson NW (1995) Characterization of adrenal masses with chemical shift and gadolinium-enhanced MR imaging. Radiology 197(2): 411-418.
28. 18F-FDG PET in evaluation of adrenal lesions in patients with lung cancer. J Nucl Med 45(12): 2058-2062.
29. Maurea S, Mainolfi C, Bazzicalupo L, Panico MR, Imparato C, Alfano B, Ziviello M, Salvatore M (1999) Imaging of adrenal tumors using FDG PET: comparison of benign and malignant lesions. AJR Am J Roentgenol 173(1): 25-29.
30. 18F-FDG PET/CT in the evaluation of adrenal masses. J Nucl Med 47(1): 32-37.
31. Minn H, Salonen A, Friberg J, Roivainen A, Viljanen T, Langsjo J, Salmi J, Valimaki M, Nagren K, Nuutila P (2004) Imaging of adrenal incidentalomas with PET using (11)C-metomidate and (18)F-FDG. J Nucl Med 45(6): 972-979.
32. 18F]FETO with respect to the adrenocortical and GABAergic system in rats. Eur J Nucl Med Mol Imaging 30(10): 1398-1401.
33. Ozcan Kara P, Kara T, Kara Gedik G, Kara F, Sahin O, Ceylan Gunay E, Sari O (2011) The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions. Nucl Med Commun 32(2): 106-112. doi: 10. 1097/MNM. 0b013e32834199e7.
34. Park BK, Kim CK, Kim B, Lee JH (2007) Comparison of delayed enhanced CT and chemical shift MR for evaluating hyperattenuating incidental adrenal masses. Radiology 243(3): 760-765.
35. Pena CS, Boland GW, Hahn PF, Lee MJ, Mueller PR (2000) Characterization of indeterminate (lipid-poor) adrenal masses: use of washout characteristics at contrast-enhanced CT. Radiology 217(3): 798-802.
36. 11C]-metomidate positron emission tomography. BMC Med Imaging 9: 6. doi: 1471-2342-9-6.
37. 18F-fluorodeoxyglucose positron emission tomography as a diagnostic tool for malignancy of adrenocortical tumours? Preliminary results in 13 consecutive patients. Eur J Endocrinol 150(6): 789-792.
38. Vikram R, Yeung HD, Macapinlac HA, Iyer RB (2008) Utility of PET/CT in differentiating benign from malignant adrenal nodules in patients with cancer. AJR Am J Roentgenol 191(5): 1545-1551.
39. 18F-FDG PET in characterizing adrenal lesions detected on CT or MRI. J Nucl Med 42(12): 1795-1799.
40. Zettinig G, Mitterhauser M, Wadsak W, Becherer A, Pirich C, Vierhapper H, Niederle B, Dudczak R, Kletter K (2004) Positron emission tomography imaging of adrenal masses: (18)F-fluorodeoxyglucose and the 11beta-hydroxylase tracer (11)C-metomidate. Eur J Nucl Med Mol Imaging 31(9): 1224-1230.